| Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study |
|
American Journal of Hematology |
Aplastic Anemia |
| Prophylaxis and management of thromboembolism in pnh patients: an italian survey |
|
Annals of Hematology & Oncology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS) |
|
Cochrane Database of Systematic Reviews |
Myelodysplastic Syndromes (MDS) |
| Development and validation of the predictive aplastic score system (PASS): a simplified tool to diagnose acquired aplastic anemia in adults |
|
Leukemia |
Aplastic Anemia |
| A Survey of Provider Practices for Diagnosis and Treatment of Pediatric Moderate Aplastic Anemia From the North American Pediatric Aplastic Anemia Consortium |
|
Journal of Pediatric Hematology/Oncology |
Aplastic Anemia |
| Allogeneic HSCT in Aplastic Anemia: Current Evidence, Controversies, and Practical Decision-Making |
|
American Journal of Hematology |
Aplastic Anemia |
| An Immune Dysfunction Signature Score Predicts Survival in MDS Patients: Insights From a Longitudinal, Multicenter Study |
|
Cancer Science |
Myelodysplastic Syndromes (MDS) |
| Allogeneic HSCT in Aplastic Anemia: Current Evidence, Controversies, and Practical Decision-Making |
|
American Journal of Hematology |
Aplastic Anemia |
| A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database |
|
Blood Cancer Journal |
Myelodysplastic Syndromes (MDS) |
